Characteristics of eyes with secondary loss of visual acuity receiving variable dosing ranibizumab for neovascular age-related macular degeneration (Q84497944)

From Wikidata

Jump to navigation Jump to search

scientific article published on 02 July 2011

Language	Label	Description	Also known as
English	Characteristics of eyes with secondary loss of visual acuity receiving variable dosing ranibizumab for neovascular age-related macular degeneration	scientific article published on 02 July 2011

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21725716%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Characteristics of eyes with secondary loss of visual acuity receiving variable dosing ranibizumab for neovascular age-related macular degeneration (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21725716%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

macular degeneration

1 reference

based on heuristic

inferred from title

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21725716

6 December 2024

author name string

Alessandro Mariani

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21725716%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Angeliki Deli

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21725716%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Aude Ambresin

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21725716%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Irmela Mantel

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21725716%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21725716

6 December 2024

publication date

2 July 2011

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21725716%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

full work available at URL

https://serval.unil.ch/resource/serval:BIB_431C65CC7872.P001/REF.pdf

Portable Document Format

online access status

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21725716

6 December 2024

http://link.springer.com/content/pdf/10.1007/s00417-011-1734-5.pdf

Portable Document Format

1 reference

10.1007/S00417-011-1734-5

https://api.crossref.org/works/10.1007/S00417-011-1734-5

6 December 2024

http://link.springer.com/article/10.1007/s00417-011-1734-5/fulltext.html

1 reference

10.1007/S00417-011-1734-5

https://api.crossref.org/works/10.1007/S00417-011-1734-5

6 December 2024

http://link.springer.com/content/pdf/10.1007/s00417-011-1734-5

1 reference

10.1007/S00417-011-1734-5

https://api.crossref.org/works/10.1007/S00417-011-1734-5

6 December 2024

Graefe's Archive for Clinical and Experimental Ophthalmology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21725716%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

249

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21725716%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21725716%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

1635-1642

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21725716%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Optical coherence tomography-measured pigment epithelial detachment height as a predictor for retinal pigment epithelial tears associated with intravitreal bevacizumab injections.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21725716

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Results of one-year's treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting

1 reference

https://pubmed.ncbi.nlm.nih.gov/21725716

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2

1 reference

https://pubmed.ncbi.nlm.nih.gov/21725716

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Retinal pigment epithelial tears after intravitreal bevacizumab injection for predominantly classic choroidal neovascularization.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21725716

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Treatment of wet AMD with less than 12 injections of Ranibizumab per year]

1 reference

https://pubmed.ncbi.nlm.nih.gov/21725716

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intravitreal bevacizumab for exudative age-related macular degeneration: effect on different subfoveal membranes

1 reference

https://pubmed.ncbi.nlm.nih.gov/21725716

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21725716

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of ranibizumab in patients with subfoveal choroidal neovascularization attributable to age-related macular degeneration

1 reference

https://pubmed.ncbi.nlm.nih.gov/21725716

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study

1 reference

https://pubmed.ncbi.nlm.nih.gov/21725716

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Results of flexible ranibizumab treatment in age-related macular degeneration and search for parameters with impact on outcome.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21725716

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration

1 reference

https://pubmed.ncbi.nlm.nih.gov/21725716

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Retinal pigment epithelial tears after intravitreal injection of bevacizumab for AMD. Frequency and progress

1 reference

https://pubmed.ncbi.nlm.nih.gov/21725716

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Retinal pigment epithelial tears after intravitreal bevacizumab injection for neovascular age-related macular degeneration.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21725716

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term visual course after anti-VEGF therapy for exudative AMD in clinical practice evaluation of the German reinjection scheme

1 reference

https://pubmed.ncbi.nlm.nih.gov/21725716

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration

1 reference

https://pubmed.ncbi.nlm.nih.gov/21725716

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration

1 reference

https://pubmed.ncbi.nlm.nih.gov/21725716

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/21725716

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ranibizumab for exudative age-related macular degeneration: 24-month outcomes from a single-centre institutional setting.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21725716

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1

1 reference

https://pubmed.ncbi.nlm.nih.gov/21725716

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results

1 reference

https://pubmed.ncbi.nlm.nih.gov/21725716

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration

1 reference

https://pubmed.ncbi.nlm.nih.gov/21725716

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study

1 reference

https://pubmed.ncbi.nlm.nih.gov/21725716

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Artifacts in automatic retinal segmentation using different optical coherence tomography instruments

1 reference

https://pubmed.ncbi.nlm.nih.gov/21725716

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ranibizumab for neovascular age-related macular degeneration

1 reference

https://pubmed.ncbi.nlm.nih.gov/21725716

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Response to ranibizumab therapy in neovascular AMD - an evaluation of good and bad responders

1 reference

https://pubmed.ncbi.nlm.nih.gov/21725716

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Retinal pigment epithelium tears after intravitreal bevacizumab in pigment epithelium detachment

1 reference

https://pubmed.ncbi.nlm.nih.gov/21725716

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Early clinical experience with ranibizumab for occult and minimally classic neovascular membranes in age-related macular degeneration

1 reference

https://pubmed.ncbi.nlm.nih.gov/21725716

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Characteristics of Patients Losing Vision after 2 Years of Monthly Dosing in the Phase III Ranibizumab Clinical Trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/21725716

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Retinal pigment epithelium tears after intravitreal injection of ranibizumab for predominantly classic neovascular membranes secondary to age-related macular degeneration.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21725716

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q84497944&oldid=2283981626"